Cell science · Investigational
Our first biotechnology product is Multilineage-differentiating Stress-Enduring cells — a rare subpopulation already resident in adult connective tissue. We work on this with Pilargo, which supplies wholesale to licensed clinics and research groups.
The biology
Muse cells are identified by a surface marker, SSEA-3, and make up roughly one to a few per cent of an ordinary mesenchymal culture. They are not engineered — they are already present, and rare.
Three properties define them in the preclinical literature. They navigate toward injured tissue by following a chemical gradient rather than arriving passively. At the injury site they engulf apoptotic debris, and that uptake directs what they differentiate into. And they express HLA-G, which has allowed allogeneic administration without tissue matching or immunosuppression across the published trials.
Six early-phase trials have been published, enrolling roughly sixty-seven patients in total. One was randomised and placebo-controlled — a stroke study reporting 40% of treated patients reaching functional independence at twelve weeks against 10% on placebo. No indication has reached Phase 3.
The limitation that matters most
No trial has ever compared a Muse preparation head to head against standard mesenchymal therapy, for any condition. Every claim of relative advantage is an inference from mechanism and animal models, not a demonstrated clinical result.
Supply
Because Muse cells are defined by a marker rather than a source tissue, the only meaningful description of a preparation is its measured SSEA-3-positive fraction. An unsorted culture and an enriched product can carry the same label and differ by an order of magnitude.
Pilargo supplies on that basis — wholesale, to licensed clinics and research groups, with batch documentation on every lot. It is a separate entity and does not treat patients.
In development
Pipeline status
Shipping — Red-Light R-100 / R-1000
Shipping — GlutaYouth™ & Rejuvenation Gel
Research — Muse cell programme (with Pilargo)
Research — further biotech programmes, early stage
We will describe new programmes when there is a specification, a measurement, or a result to describe — not before.
Further biotechnology programmes are in development. We will describe them when there is something specific to describe — a specification, a measurement, a result. Until then there is nothing here worth reading, and we would rather leave the section short than fill it.